Livongo Health, Inc. is slated to release second-quarter 2020 results on Aug 6, after the opening bell. In the last reported quarter, the company delivered an earnings surprise of 175%. Further, it beat estimates in each of the trailing four quarters, the average surprise being 95.2%. Q2 Estimates
For the second quarter, the Zacks Consensus Estimate for revenues is pegged at $84.3 million, suggesting growth of 106.2% from the prior-year quarter. The same for earnings per share is pegged at 1 cent.
Factors to Note
Livongo Health second-quarter results are likely to reflect growth in core Livongo for Diabetes solution. Substantial contributions from hypertension, weight management and behavorial health offerings might have acted as catalysts. In fact, per the preliminary announcement, the company anticipates revenues between $86 million and $87 million (up from the previously guided range of $73-$75 million).
Further, continued strong demand in the company’s pipeline, rise in member enrollment and new client signings might have contributed to the second-quarter performance.
Additionally, the company is expected to display favorable gross margin on the back of higher incremental margins from members who continue to stay on its platform.
Livongo Health has been witnessing higher adoption of both of its core diabetes offering and other offerings. Further, apart from expediting the adoption of Livongo for Diabetes in the self-insured market, the company has been successfully expanding into fully-insured and government markets. This might get reflected in the second-quarter results. Further, expansion of strategic agreements with key channel partners include CVS Health and Express Scripts are driving sales across multiple conditions. However, the Livongo Health may have experienced a rise in operating expenses, which in turn can weigh on its performance in the to-be-reported quarter. What Our Quantitative Model Suggests
Per our proven model, the combination of a positive
Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see. Earnings ESP: Livongo Health has an Earnings ESP of +124.99%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: Livongo Health carries a Zacks Rank #3. Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
Integra LifeSciences Holdings Corporation ( IART Quick Quote IART - Free Report) has an Earnings ESP of +20.69% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here. GW Pharmaceuticals plc ( GWPH Quick Quote GWPH - Free Report) has an Earnings ESP of +17.38% and a Zacks Rank of 3. Nevro Corp. ( NVRO Quick Quote NVRO - Free Report) has an Earnings ESP of +15.17% and a Zacks Rank of 3. Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>